Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Table 4

Univariate analysis of factors related to response.

	Primary liver cancer		Secondary liver cancer
	Nonresponse/response	value	Nonresponse/response	value
Sex
Male	21/16	0.25	7/3	0.74
Female	4/0		5/3
Ablation history
No	21/15	0.35	7/6	0.19
Yes	4/1		5/0
TKI history
No	19/15	0.29	7/4	0.73
Yes	6/1		5/2
c-TACE history
No	7/11	0.11	8/6	0.28
Yes	18/5		4/0
Tumor diameter
<50 mm	9/7	0.87	9/4	0.71
≥50 mm	16/9		3/2

TKI: tyrosine kinase inhibitor; TACE: transarterial chemoembolization.